EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Supervisory Board

16.03.2012

Berlin, Germany, March 16, 2012 - Epigenomics AG (ISIN: DE000A1K0516)
today decided to propose to the shareholders of the company at the
upcoming Annual General Meeting on May 2, 2012 to vote in favor of a
reduction of the size of the Supervisory Board from currently six to
three members. Furthermore, the company's Chairman, Prof. Dr. Dr.
h.c. Rolf Krebs, announced that for personal reasons he will not
stand for re-election at the upcoming Annual General Meeting.

Prof. Dr. Rolf Krebs (72) has been a member of the Supervisory Board
of Epigenomics AG since 2000 and its Chairman since 2003. During this
period, the company has evolved from a privately held start-up
research company to a publicly listed, worldwide commercial leader in
the field of blood based products for the early detection of cancer.

The Supervisory Board has further resolved to propose Mr. Heino von
Prondzynski for election to the Supervisory Board by the Annual
General Meeting. Mr. von Prondzynski has indicated his willingness to
accept the role as Chairman of the Supervisory Board in case of his
election.

Heino von Prondzynski (62) is an internationally recognized expert
and accomplished business leader in the field of molecular
diagnostics with an extensive network of contacts in the US, Europe
and beyond. Among other career accomplishments, he has been CEO of
the diagnostics division of F. Hoffmann-La Roche Ltd., Basel,
Switzerland and a member of the group executive committee of Roche.
He is intimately acquainted with the company, having been a member of
the Supervisory Board of Epigenomics from May 2007 until March 2010.

In addition to Mr. von Prondzynski, current members of the
Supervisory Board, Ms. Kessler, Ph.D. and Prof. Dr. Reiter, will be
seeking election at the upcoming Annual General Meeting.

The proposed changes to the Supervisory Board structure and
composition have been thoroughly planned and were made in line with
last year's decision to reinforce the focus of the company's
operations on the key US market. Heino von Prondzynski has indicated
his intention to work closely with the management team to diligently
explore all viable strategic options for the company in its further
development, including, but not limited to, the possibility of
securing additional financial resources to support the company's
operations beyond the current cash reach. A main operational goal of
the company remains to gain approval for and subsequently introduce
Septin9 based colorectal cancer screening tests in the US market. -
End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English